Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the results of completed studies of nonspecific microbicides for prevention of HIV
- Discuss the preclinical and animal model data supporting the use of antiretrovirals for HIV prevention
- Cite studies of oral and topical tenofovir or tenofovir/emtricitabine that will assess their activity in reducing HIV infections
- Summarize the additional bridging studies that will be needed before oral or topical pre-exposure prophylaxis can be operationalized
Topics covered include:
- Introduction
- Nonspecific Microbicides Used Before Sex for Prevention of HIV
- Animal Studies Supporting the Use of Antiretroviral Drugs for PrEP
- Clinical Studies of Oral PrEP
- Preclinical Studies Supporting Topical Antiretrovirals for PrEP
- Clinical Studies of Topical Antiretrovirals for PrEP
- Populations That Will Require Bridging Studies
- Future Issues
Abstract